Look for Drugs and Conditions

Colfosceril Polmitate

Colfosceril Polmitate

Colfosceril palmitate is a phospholipid. It forms an important constituent of natural and many synthetic pulmonary surfactant compounds. Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting pressures. Deficiency of surfactant causes respiratory distress syndrome (RDS) in premature infants. Colfosceril lowers minimum surface tension on alveolar surfaces and restores pulmonary compliance and oxygenation in premature infants.

Indications

Endotracheal Prophylaxis Infant: Intratracheal 3 doses of 5 mL/kg are recommended, with the first dose being given as soon as possible after birth and repeat doses 12 and 24 h later to infants who remain on mechanical ventilation Rescue Therapy Infant: Intratracheal 2 doses of 5 mL/kg are recommended, the first dose being initiated as soon as the diagnosis of RDS is confirmed and the second 12 h later in infants remaining on mechanical ventilation


Contra-Indications

Infants who have major congenital abnormalities or who are suspected of having congenital infections.


Special Precautions

Monitor continuously for 30 min following administration. ECG and transcutaneous monitoring are required, frequent arterial blood gas sampling is required


Side Effects

Bradycardia, tachycardia, Decreased oxygen saturation, mucous plugging, apnea, pulmonary hemorrhage.


Drug Interactions

No clinically significant interactions established.


Other Brands With Same Generic
Brand Name Manufactured by
SURFACT Sun Pharmaceutical Industries Ltd.
Ad 5